Literature DB >> 17979680

Immune responses to gene product of inducible promoters.

Caroline Le Guiner1, Knut Stieger, Richard O Snyder, Fabienne Rolling, Philippe Moullier.   

Abstract

Efficient gene transfer has been achieved in several animal models using different vector systems, leading to stable transgene expression. The tight control of this expression is now an important outcome for the field of gene therapy. Such regulation is likely to be required for therapeutic applications and in some instances for safety reasons. For this purpose, several regulatable systems depending on small molecules have been developed. Among these, the tetracycline and the rapamycin dependent systems have been largely used. However, if long-term regulation of the transgene has been obtained in small animal models using these inducible systems, when translational studies were initiated in larger animals, the development of an immune response against proteins involved in transgene regulation were often observed. Such immune response was especially documented when using the TetOn tetracycline regulatable system in nonhuman primates (NHP). Humoral and destructive cellular immune responses against the transactivator involved in this regulation system were documented in a large majority of NHP leading to the complete loss of the transgene regulation and expression. This review will describe the immune responses observed in these different model systems applied for transgene regulation. Focus will be finally given on future directions in which such immune responses might be surmounted, enabling long-term transgene regulation in future clinical developments of gene transfer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17979680     DOI: 10.2174/156652307782151461

Source DB:  PubMed          Journal:  Curr Gene Ther        ISSN: 1566-5232            Impact factor:   4.391


  19 in total

1.  An adaptable system for improving transposon-based gene expression in vivo via transient transgene repression.

Authors:  Joseph E Doherty; Lauren E Woodard; Adham S Bear; Aaron E Foster; Matthew H Wilson
Journal:  FASEB J       Date:  2013-06-10       Impact factor: 5.191

2.  PiggyBac transposon-based inducible gene expression in vivo after somatic cell gene transfer.

Authors:  Sai K Saridey; Li Liu; Joseph E Doherty; Aparna Kaja; Daniel L Galvan; Bradley S Fletcher; Matthew H Wilson
Journal:  Mol Ther       Date:  2009-10-06       Impact factor: 11.454

3.  Modulation of immunogenicity and immunoprotection of mucosal vaccine against coxsackievirus B3 by optimizing the coadministration mode of lymphotactin adjuvant.

Authors:  Yan Yue; Wei Xu; Sidong Xiong
Journal:  DNA Cell Biol       Date:  2011-10-11       Impact factor: 3.311

Review 4.  Barriers for retinal gene therapy: separating fact from fiction.

Authors:  Rajendra Kumar-Singh
Journal:  Vision Res       Date:  2008-06-18       Impact factor: 1.886

5.  Transgene-specific host responses in cutaneous gene therapy: the role of cells expressing the transgene.

Authors:  Z Zhang; C Kuscu; S Ghazizadeh
Journal:  Gene Ther       Date:  2009-05-14       Impact factor: 5.250

6.  Tolerance induction to cytoplasmic beta-galactosidase by hepatic AAV gene transfer: implications for antigen presentation and immunotoxicity.

Authors:  Ashley T Martino; Sushrusha Nayak; Brad E Hoffman; Mario Cooper; Gongxian Liao; David M Markusic; Barry J Byrne; Cox Terhorst; Roland W Herzog
Journal:  PLoS One       Date:  2009-08-04       Impact factor: 3.240

Review 7.  Non-coding RNA therapeutics for cardiac regeneration.

Authors:  Luca Braga; Hashim Ali; Ilaria Secco; Mauro Giacca
Journal:  Cardiovasc Res       Date:  2021-02-22       Impact factor: 10.787

8.  Graded or threshold response of the tet-controlled gene expression: all depends on the concentration of the transactivator.

Authors:  Niels Heinz; Katharina Hennig; Rainer Loew
Journal:  BMC Biotechnol       Date:  2013-01-22       Impact factor: 2.563

9.  Specific micro RNA-regulated TetR-KRAB transcriptional control of transgene expression in viral vector-transduced cells.

Authors:  Virginie Pichard; Dominique Aubert; Sebastien Boni; Severine Battaglia; Dejana Ivacik; Tuan Huy Nguyen; Patrick Arbuthnot; Nicolas Ferry
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

10.  Fibrinogen-like protein 2/fibroleukin induces long-term allograft survival in a rat model through regulatory B cells.

Authors:  Séverine Bézie; Elodie Picarda; Laurent Tesson; Karine Renaudin; Justine Durand; Séverine Ménoret; Emmanuel Mérieau; Elise Chiffoleau; Carole Guillonneau; Lise Caron; Ignacio Anegon
Journal:  PLoS One       Date:  2015-03-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.